Clinical Trial Update: Efficacy of [18F]Florbetaben PET for Diagnosis of Cardiac AL Amyloidosis [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating [18F]Florbetaben PET for diagnosing Cardiac AL Amyloidosis has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Al Amyloidosis
• Cardiac Amyloidosis

Drugs mentioned

• 18F-Florbetaben

Snippet

Sponsor: Lantheus Germany GmbH | Conditions: Cardiac Amyloidosis, AL Amyloidosis | Phase 3 | Status: COMPLETED